{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:20:05Z","timestamp":1790878805534,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypersensitive C-reactive protein-atherogenic index (CAI) may serve as a novel marker for metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM). This study aimed to evaluate the association between CAI and MASLD risk, while comparing its diagnostic performance with C-reactive protein-triglyceride glucose index (CTI), triglyceride-glucose (TyG) index, and atherogenic index of plasma (AIP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>The final cohort included 1,071 individuals with T2DM from the Metabolic Management Center of our hospital. The association between CAI and MASLD was assessed by the binomial logistic regression, restricted cubic splines (RCS), and subgroup analysis. Receiver operating characteristic curve analysis was performed to evaluate the diagnostic performance of CAI for MASLD, with DeLong analysis used to compare its diagnostic ability to CTI, TyG index, and AIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Individuals in the higher CAI quartiles demonstrated a greater prevalence of MASLD (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). After adjusting for confounding factors, CAI was independently associated with a higher risk of MASLD (\n                      <jats:italic>OR:<\/jats:italic>\n                      2.14, 95% CI: 1.74-2.62,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Each SD increase in CAI was associated with a 99% higher risk of MASLD (\n                      <jats:italic>OR:<\/jats:italic>\n                      1.99, 95% CI: 1.65-2.39,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). These associations persisted across subgroups of sex, anti-hepatic steatosis hypoglycemic agent, hypertension, alcohol consumption, and statin use (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). RCS analysis revealed a linear association between CAI and risk of MASLD (\n                      <jats:italic>P<\/jats:italic>\n                      for nonlinearity = 0.357). ROC analysis indicated that CAI had a diagnostic ability for MASLD (AUC:0.732, 95%CI:0.702-0.762), outperforming CTI (AUC difference: 0.020, 95% CI: 0.007-0.034,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003), TyG (AUC difference: 0.044, 95% CI: 0.026-0.062,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and AIP (AUC difference: 0.022, 95% CI: 0.011-0.033,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) in the DeLong analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CAI could serve as a novel marker for screening high-risk populations for MASLD in T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1721278","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:17:39Z","timestamp":1763529459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hypersensitive C-reactive protein-atherogenic index as a novel marker for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101898","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990\u20132021 to 2045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the american diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Alimentary Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","article-title":"The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects","volume":"6","author":"Simental-Mend\u00eda","year":"2008","journal-title":"Metab Syndrome Related Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-023-02115-9","article-title":"The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003-2018","volume":"23","author":"Dang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13098-024-01258-3","article-title":"A higher TyG index level is more likely to have enhanced incidence of T2DM and HTN comorbidity in elderly Chinese people: a prospective observational study from the reaction study","volume":"16","author":"Su","year":"2024","journal-title":"Diabetol Metab Syndrome"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2022.07.024","article-title":"The accuracy of triglyceride-glucose (TyG) index for the screening of metabolic syndrome in adults: A systematic review and meta-analysis","volume":"32","author":"Nabipoorashrafi","year":"2022","journal-title":"Nutrition Metabolism Cardiovasc Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5871321","DOI":"10.1155\/cjgh\/5871321","article-title":"The value of tyG-related indices in evaluating MASLD and significant liver fibrosis in MASLD","volume":"2025","author":"Zou","year":"2025","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200717090334","article-title":"High sensitivity C-reactive protein (hsCRP) and its implications in cardiovascular outcomes","volume":"27","author":"Denegri","year":"2021","journal-title":"Curr Pharm Design"},{"key":"B12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s40001-024-02065-2","article-title":"High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver disease in non-obese people: a cross-sectional study","volume":"29","author":"Xia","year":"2024","journal-title":"Eur J Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.905266","article-title":"A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12933-025-02848-9","article-title":"C-reactive protein-triglyceride glucose index in evaluating cardiovascular disease and all-cause mortality incidence among individuals across stages 0\u20133 of cardiovascular-kidney-metabolic syndrome: a nationwide prospective cohort study","volume":"24","author":"Ou","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12933-025-02876-5","article-title":"Association between the C-reactive protein-triglyceride glucose index and new-onset coronary heart disease among metabolically heterogeneous individuals","volume":"24","author":"Chen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12876-025-03870-7","article-title":"Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12944-021-01505-w","article-title":"Visceral adiposity index and atherogenic index of plasma as useful predictors of risk of cardiovascular diseases: evidence from a cohort study in Iran","volume":"20","author":"Hamzeh","year":"2021","journal-title":"Lipids Health Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12933-024-02144-y","article-title":"Association between atherogenic index of plasma control level and incident cardiovascular disease in middle-aged and elderly Chinese individuals with abnormal glucose metabolism","volume":"23","author":"Min","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12933-025-02593-z","article-title":"Correlation between atherogenic index of plasma and cardiovascular disease risk across Cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study","volume":"24","author":"Hu","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1038\/s41598-025-93141-y","article-title":"Atherogenic index of plasma identifies subjects with severe liver steatosis","volume":"15","author":"De Matteis","year":"2025","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12933-024-02446-1","article-title":"Multiple triglyceride-derived metabolic indices and incident cardiovascular outcomes in patients with type 2 diabetes and coronary heart disease","volume":"23","author":"Tao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: A meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2019.08.009","article-title":"Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses","volume":"50","author":"Fern\u00e1ndez-Mac\u00edas","year":"2019","journal-title":"Arch Med Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2012.02.022","article-title":"Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis","volume":"19","author":"Zeb","year":"2012","journal-title":"Acad Radiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-03895-6","article-title":"Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030","volume":"20","author":"Huang","year":"2025","journal-title":"Internal Emergency Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12876-025-03912-0","article-title":"Clinical characteristics of MASLD\/MetALD\/MAFLD\/NAFLD and the relative risk analysis on metabolic disorders","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"BMJ (Clinical Res ed)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"110191","DOI":"10.1016\/j.diabres.2022.110191","article-title":"The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study","volume":"194","author":"Park","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0130","article-title":"Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Seo","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","article-title":"Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","article-title":"Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank","volume":"24","author":"Qiao","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1083032","article-title":"Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults","volume":"14","author":"Peng","year":"2023","journal-title":"Front Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3390\/jcm14103405","article-title":"Association between visceral adiposity and the prediction of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"14","author":"Bende","year":"2025","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12902-024-01794-z","article-title":"The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes","volume":"24","author":"Tian","year":"2024","journal-title":"BMC Endocrine Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12902-022-00993-w","article-title":"Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes","volume":"22","author":"Li","year":"2022","journal-title":"BMC Endocrine Disord"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1425024","article-title":"Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus","volume":"15","author":"Qian","year":"2024","journal-title":"Front Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1127134","article-title":"Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S375300","article-title":"A cross-sectional study of the correlation between the atherogenic index of plasma and nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"15","author":"Lin","year":"2022","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1384059","article-title":"Triglycerides to apolipoprotein A1 ratio: an effective insulin resistance-associated index in identifying metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9560","DOI":"10.3390\/ijms26199560","article-title":"Creatinine-to-cystatin C ratio combined with FIB-4 and ELF for noninvasive fibrosis assessment in MASLD","volume":"26","author":"Oyama","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1038\/s41598-024-58205-5","article-title":"ALBI score combined with FIB-4 index to predict post-hepatectomy liver failure in patients with hepatocellular carcinoma","volume":"14","author":"Tian","year":"2024","journal-title":"Sci Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721278\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:17:40Z","timestamp":1763529460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721278\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":42,"alternative-id":["10.3389\/fendo.2025.1721278"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1721278","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1721278"}}